Construct and Predictive Validity of the Kansas City Cardiomyopathy Questionnaire in Adult Congenital Heart Disease

堪萨斯城心肌病问卷在成人先天性心脏病中的结构效度和预测效度

阅读:1

Abstract

BACKGROUND: The Kansas City Cardiomyopathy Questionnaire (KCCQ) is an Food and Drug Administration-approved health status measure for patients with heart failure (HF) but has not been directly assessed in adult congenital heart disease (ACHD). OBJECTIVES: This study evaluates construct and predictive validity of the KCCQ in ambulatory ACHD patients. METHODS: We performed cross-sectional and prospective cohort studies of ACHD patients who completed the KCCQ to assess construct and predictive validity, respectively. KCCQ scores were compared across ACHD complexity categories, disease characteristics and physiologic failure, and within 2 primary composite outcomes: death or all-cause hospitalization (DH) and death or interventional cardiac procedures (DP). Survival analysis was performed for each composite outcome. RESULTS: A total of 109 patients completed 129 KCCQs (median age 29.0 years; 41.3% female). Median KCCQ scores were significantly lower for anatomically complex patients (76.6 in great complexity, 89.0 in simple/moderate complexity; P = 0.015), advanced ACHD physiological stage (72.6 in D, 98.0 in A; P < 0.001), patients with physician-reported HF (72.2 vs 87.2 without HF; P < 0.001), and advanced NYHA functional class (NYHA III: 44.4, NYHA I: 96.5; P < 0.001). Median follow-up time was 16.3 months in the predictive validity analysis (N = 92). KCCQ was significantly lower for ACHD patients who experienced DH (66.0 vs 85.0; P = 0.002) or DP (53.5 vs 85.0; P = 0.001). Patients scoring ≤50 had significantly worse event-free survival (P = 0.004 for DH; P = 0.001 for DP). CONCLUSIONS: The KCCQ has construct and predictive utility in ACHD and provides an opportunity to assess health status in ACHD both clinically and in future ACHD research.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。